North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type (Dry AMD, and Wet AMD), By Drug Type (Aflibercept (Eylea), Ranibizumab (Lucentis), Bevacizumab (Avastin), Pegaptanib (Macugen), Verteporfin (Visudyne), Brolucizumab (Beovu), Supplements, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America and Europe), is estimated to be valued at US$ 9,958.7 million in 2020 and is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing prevalence of age-related macular degeneration is expected to drive the market growth during the forecast period. According to the report published by the European Society of Retina Specialist, in 2017, around 34 million people in the European Union (EU) and 22 million people in the five most populous European countries (Germany, France, the U.K., Italy, and Spain) were affected by the age-related macular degeneration disease

North America & Europe Age-related Macular Degeneration Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

Small and medium ophthalmology practices have been completely shut down owing to nationwide lockdowns in key regions and only large ophthalmology practices are open which are dealing with emergency cases. This has reduced the number of patient visits to ophthalmology clinics.

However, healthcare providers are adopting telehealth solutions for cancer patients while maintain social distancing to combat COVID-19 pandemic without compromising the health of patients. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking the following measures to reduce the spread of COVID-19.

  • Hospitals have restricted entry of visitors and only emergency cases are being handled.
  • Screening for possible symptoms of COVID-19 is being performed for all the people who are entering the hospitals.
  • Healthcare providers are encouraging patients to schedule appointments via telemedicine platforms.

Browse 46 Market Data Tables and 37 Figures spread through 166 Pages and in-depth TOC on “North America & Europe Age-related Macular Degeneration Market”- North America & Europe Forecast to 2027, North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type (Dry AMD, and Wet AMD), By Drug Type (Aflibercept (Eylea), Ranibizumab (Lucentis), Bevacizumab (Avastin), Pegaptanib (Macugen), Verteporfin (Visudyne), Brolucizumab (Beovu), Supplements, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, and Europe).

To know the latest trends and insights prevalent in the North America & Europe Age-related Macular Degeneration Therapeutics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/north-america-and-europe-age-related-macular-degeneration-therapeutics-market-4171

Market players are focusing on inorganic strategies such as collaborations, partnerships, and agreements to enhance their product portfolio and strengthen their market presence. For instance, on September 2019, Boehringer Ingelheim entered a partnership agreement (a co-development and license agreement) with Inflammasome Therapeutics Inc. for development of three therapies targeting retinal diseases including age related macular degeneration, diabetic retinopathy (DR), and diabetic macular edema (DME).

Key Takeaways of the North America & Europe Age-related Macular Degeneration Therapeutics Market:

  • The North America & Europe age-related macular degeneration therapeutics market is expected to exhibit a CAGR of 6.1% during the forecast period owing to launches of age-related macular degeneration therapeutics by market players. For instance, in June 2016, Intas Pharmaceuticals launched RAZUMAB, a biosimilar to Lucentis (Ranibizumab). It is indicated for treatment of Neovascular (Wet) age-related macular degeneration (AMD).
  • Based on disease type, the Dry AMD segment accounted for the largest market share in 2019 due to research and development by market players. For instance, in October 2019, LumiThera Inc., a medical device company initiated patient enrollment for a multi-center U.S. clinical study, LIGHTSITE III, for the treatment of dry age-related macular degeneration (AMD).
  • Based on drug type, the Aflibercept (Eylea) segment accounted for the largest market share in 2019, owing to adoption of research and development activities by market players. For instance, in February 2020, Bayer AG and Regeneron Pharmaceuticals, Inc. announced the initiation of two phase III studies, PHOTON and PULSAR for the evaluation of extended treatment intervals with aflibercept 8mg formulation for the treatment of wet age-related macular degeneration (wet AMD).
  • Key players operating in the North America & Europe age-related macular degeneration therapeutics market are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner